F Xie1, P Li2, J Gong1, H Tan1, J Ma3. 1. Department of Respiratory Medicine, The Second Clinical Medical College, Yangtze University, Renmin Road 1, Jingzhou, 434020, People's Republic of China. 2. Department of Medical Oncology, Tongji Medical College, Huazhong University of Science and Technology (HUST), Wuhan, People's Republic of China. 3. Department of Respiratory Medicine, The Second Clinical Medical College, Yangtze University, Renmin Road 1, Jingzhou, 434020, People's Republic of China. mjpjzhospital@hotmail.com.
Abstract
BACKGROUND: KRAS mutations are prevalent in non-small cell lung cancer (NSCLC) but its clinical implications remain to be determined. Continual profiling of KRAS mutations in patients is challenging, and the study aims to determine the potential use of urinary DNA in disease predictions. METHODS: A total of 150 patients were recruited. To ascertain the clinical relevance of urinary DNA, matched tumor profiles were analyzed. Serial measurements were taken to gauge the reliability of the assay. These results were correlated to overall survival using the Kaplan-Meier estimate. RESULTS: A good overall concordance of 93% (consolidated results from serial measurements) was achieved between tumor tissue and urinary DNA profiling. Of the discordant KRAS cases, we observed subsequent positive detection during monitoring and very low concentrations of mutant DNA. In addition, we noted that KRAS-positive patients detected using urinary DNA have good prognostic utility. Interestingly, we also observed that the trend is highly correlative of the rate of change in KRAS mutant DNA concentrations and the period of monitoring. CONCLUSIONS: Urinary DNA offered a non-invasive approach to probe NSCLC dynamics, and in our study we showed that it had predictive capabilities for KRAS-positive patients. Serial monitoring of urinary samples showed that it had a predictive role in identifying patients with worse outcome.
BACKGROUND:KRAS mutations are prevalent in non-small cell lung cancer (NSCLC) but its clinical implications remain to be determined. Continual profiling of KRAS mutations in patients is challenging, and the study aims to determine the potential use of urinary DNA in disease predictions. METHODS: A total of 150 patients were recruited. To ascertain the clinical relevance of urinary DNA, matched tumor profiles were analyzed. Serial measurements were taken to gauge the reliability of the assay. These results were correlated to overall survival using the Kaplan-Meier estimate. RESULTS: A good overall concordance of 93% (consolidated results from serial measurements) was achieved between tumor tissue and urinary DNA profiling. Of the discordant KRAS cases, we observed subsequent positive detection during monitoring and very low concentrations of mutant DNA. In addition, we noted that KRAS-positive patients detected using urinary DNA have good prognostic utility. Interestingly, we also observed that the trend is highly correlative of the rate of change in KRAS mutant DNA concentrations and the period of monitoring. CONCLUSIONS: Urinary DNA offered a non-invasive approach to probe NSCLC dynamics, and in our study we showed that it had predictive capabilities for KRAS-positive patients. Serial monitoring of urinary samples showed that it had a predictive role in identifying patients with worse outcome.
Authors: Alexa B Turke; Kreshnik Zejnullahu; Yi-Long Wu; Youngchul Song; Dora Dias-Santagata; Eugene Lifshits; Luca Toschi; Andrew Rogers; Tony Mok; Lecia Sequist; Neal I Lindeman; Carly Murphy; Sara Akhavanfard; Beow Y Yeap; Yun Xiao; Marzia Capelletti; A John Iafrate; Charles Lee; James G Christensen; Jeffrey A Engelman; Pasi A Jänne Journal: Cancer Cell Date: 2010-01-19 Impact factor: 31.743
Authors: Tibor Szarvas; Ilona Kovalszky; Katalin Bedi; Attila Szendroi; Attila Majoros; Péter Riesz; Tibor Füle; Viktória László; András Kiss; Imre Romics Journal: Oncol Rep Date: 2007-08 Impact factor: 3.906
Authors: Antonio Marchetti; Maela Del Grammastro; Lara Felicioni; Sara Malatesta; Giampaolo Filice; Irene Centi; Tommaso De Pas; Armando Santoro; Antonio Chella; Alba Ariela Brandes; Paola Venturino; Franco Cuccurullo; Lucio Crinò; Fiamma Buttitta Journal: PLoS One Date: 2014-08-19 Impact factor: 3.240